Oncolytics Biotech Inc. (NASDAQ:ONCY)
Industry: Healthcare

OFF LIST - 803 consecutive market days: OFF LIST as of 03/27/2013 Through 11/14/2016

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. It has collaboration with PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Current Quote*
Last: $1.120
Change: 0.000
Book: $2.786
Volume: 273,882

As Of: 12/12 12:32 ET
*Quotes delayed by 20min.

Graphs for ONCY


3 Month Graph


6 Month Graph


1 Year Graph